GENOMICS IS TODAY, BUT
Learn more about our revolutionary
We offer novel lipid analysis based on Lipotype Shotgun Lipidomics Technology. Our innovative technology can be employed for lipid identification and absolute quantification in basic and clinical research, for the food and cosmetics industry, for routine clinical diagnostics and for personalized health care. For the first time, customers can analyze large sample numbers at reasonable cost in short time with ultra-broad coverage of lipids absolutely quantified to develop new products in medical, nutritional and cosmetics markets.
A Max Planck-Institutes spin-off company with leading experts in lipidomics
Lipotype offers high quality lipid analysis services with its Lipotype Shotgun Lipidomics Technology for a wide range of customers and applications including biomarker identification for clinical researchers, pharma and biotech companies, functional food development for the food industry, claim support for the cosmetics industry, as well as for the small-scale profiling needs of academic researchers.
Modern lipidomics supplies a fully quantitative description of lipidomes down to the level of individual lipid molecules. Lipidomics provides together with e.g. genomics, proteomics and metabolomics the »omics« foundation for advanced system biology. Lipidomics belongs to the overall metabolomics market with a particular focus on lipids.
Lipotype GmbH is supported and receives funding by the European Regional Development Fund ERDF and the Free State of Saxony to further develop its Lipotype Shotgun Lipidomics Technology and for lipid biomarker identification.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY) and under grant agreement No 115974 (Beat-DKD). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2. The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.